Can Fayuvi FDA approval lift RARE stock further?

How 1 sources are covering this

• Economic TimesLean R·3h ago

  Can Fayuvi FDA approval lift RARE stock further?

  Ultragenyx Pharmaceutical shares surged 12.6% after FDA approval of Fayuvi, its gene therapy for Sanfilippo syndrome Type A, though the RARE stock remains down sharply year-to-date following a failed trial.

  Read at Economic Times →